Premier Alternatives

Alebund Pharmaceuticals

Shanghai, China · Founded 2018 · In IPO Registration

Operator of a biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund Pharmaceuticals is based in Shanghai, China and was founded in 2018. Its last reported valuation was $530 million in Oct 2025. It has raised $270 million.

Last reported valuation
$530.5M
Oct 2026
Priced at
—
Total raised
$269.8M
Last round
—

Alebund Pharmaceuticals key facts

as of Oct 2026
  • Operator of a biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.
  • Alebund Pharmaceuticals is valued at approximately $530.5M as of Oct 2026 (last reported valuation).
  • It has raised $269.8M; the latest was IPO in Oct 2025.
  • Notable investors include GIC Private, 5Y Capital, YuanBio Venture Capital, Tencent Investment, Morningside Group — 25 tracked in total.
  • Status: In IPO Registration.
Last reported valuation
LOW confidence
$530.5M

Alebund Pharmaceuticals's last reported valuation, Oct 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Alebund Pharmaceuticals with a free account
  • ·The complete investor list: 25 names
  • ·Watch Alebund Pharmaceuticals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Alebund Pharmaceuticals funding rounds

No rounds on record

No funding rounds for Alebund Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Alebund Pharmaceuticals valuation

Alebund Pharmaceuticals's last reported valuation was $530 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.

Alebund Pharmaceuticals investors

25 investors are on record for Alebund Pharmaceuticals, including GIC Private, 5Y Capital, YuanBio Venture Capital and Tencent Investment. By type, the record holds 5 venture capital firms and 2 hedge funds.

About Alebund Pharmaceuticals

Operator of a biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. The company engages in the research, development, regulatory and commercialization of renal medicines, and has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease, thereby providing high-quality comprehensive solutions to the renal disease patients for the long-term.

Sector
Healthcare
HQ
Shanghai, China
Founded
2018
Employees
155
Ownership
In IPO Registration

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.